Key considerations in the pharmacological management of treatment-resistant depression. | Expert Opin Pharmacother;22(17): 2405-2415, 2021 Dec. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Key considerations in the pharmacological management of treatment-resistant depression.

Yavi, Mani; Henter, Ioline D; Park, Lawrence T; Zarate, Carlos.

Affiliation

Yavi M; Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental HealthNational Institutes of Health Bethesda, MD, USA.

Expert Opin Pharmacother ; 22(17): 2405-2415, 2021 Dec.

Article in En | MEDLINE | ID: mdl-34252320

Subject(s)
Key words

Augmentation; biomarkers; depression; guidelines; ketamine; management; treatment-resistant

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Depression / Depressive Disorder, Treatment-Resistant Type of study: Guideline Limits: Humans Language: En Journal: Expert Opin Pharmacother Journal subject: FARMACOLOGIA Year: 2021 Document type: Article Affiliation country:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Depression / Depressive Disorder, Treatment-Resistant Type of study: Guideline Limits: Humans Language: En Journal: Expert Opin Pharmacother Journal subject: FARMACOLOGIA Year: 2021 Document type: Article Affiliation country: